Neuronetics ($STIM): Growth Is Real, but the Balance Sheet Owns the Debate

Executive Summary

Neuronetics is no longer a simple medical-device company. Following the December 2024 acquisition of Greenbrook, it became a vertically integrated interventional mental-health platform: it sells NeuroStar transcranial magnetic stimulation systems, earns recurring treatment-session revenue from installed devices and operates company-controlled clinics that deliver TMS and SPRAVATO therapy. The transformation nearly doubled reported revenue in 2025, while pro-forma growth showed that the combined business was also expanding underneath the accounting step-up.

The equity debate therefore has two levels. The first is operational: can Greenbrook clinics keep growing, can treatment-session revenue recover, can management move gross margin back toward 47%–49%, and can the combined platform approach cash-flow breakeven? The second is financial: can those improvements arrive before unrestricted liquidity becomes too tight, and can the company amend, refinance or satisfy the March 2027 revenue covenant without issuing a damaging amount of stock?

The near-term setup is unusually sensitive to a small group of variables. Q2 revenue around the high-$39 million to low-$40 million area would be broadly consistent with management’s “mid-single-digit” growth language against Q2 2025. But the higher-quality signal will be cash: after using $9.4 million in Q1, the company must limit additional operating cash use to roughly $3.6 million–$7.6 million over the final nine months to land inside its full-year guidance. That is a demanding bridge, not a routine extrapolation.

Why $STIM Matters Now

STIM sits at the intersection of several themes that can attract small-cap healthcare investors: treatment-resistant depression, non-drug therapies, rapidly changing interventional psychiatry, clinic consolidation, reimbursement expansion and the possible arrival of psychedelic-assisted therapies. Yet the stock also carries the features that can punish investors in this segment: heavy debt, negative cash flow, acquisition integration, a large shareholder with influence, activist pressure and accessible equity issuance capacity.

Recent trading also shows that STIM can detach sharply from a calm fundamental narrative. The stock reached an intraday high of $2.33 on July 16 on approximately 11.9 million shares of volume, then closed July 17 at $1.62. Without a new official corporate announcement explaining every move, investors should resist retrofitting a fundamental story onto volatile price action. The stock has a small equity value, concentrated ownership and material event sensitivity; those characteristics can amplify both rallies and reversals.

Company Overview: A Device Business Wrapped Around a Clinic Network

Neuronetics is a commercial-stage medical-technology and healthcare-services company based in Malvern, Pennsylvania. Its original franchise is the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation platform. The company expanded into direct patient care by acquiring Greenbrook, which operates interventional psychiatry clinics across the United States.

The combined company reports two practical economic engines:

Q1 clinic revenue represented roughly 63% of U.S. revenue. Treatment sessions represented about 27% and systems about 9%. That mix explains why headline revenue growth can coexist with lower consolidated gross margin: services provide scale and strategic control, while product and recurring session economics can be more attractive at the gross-profit level.

NeuroStar TMS: Product, FDA Clearances and Reimbursement

NeuroStar delivers transcranial magnetic stimulation using pulsed magnetic fields designed to induce electrical currents in targeted brain regions. Treatment is non-systemic and non-invasive, which differentiates it from oral drugs and implanted devices. The platform is prescription-only and is used in supervised clinical settings.

FDA-cleared indications

According to Neuronetics’ SEC filings and product disclosures, NeuroStar is cleared in the United States for:

• adult patients with major depressive disorder who failed to achieve satisfactory improvement from prior antidepressant medication in the current episode;
• use as an adjunct for adults with obsessive-compulsive disorder;
• decreasing anxiety symptoms in adults with major depressive disorder and comorbid anxiety symptoms; and
• first-line adjunctive treatment of major depressive disorder in adolescents aged 15–21.

The adolescent clearance expanded the addressable population and gave NeuroStar a differentiated commercial talking point. However, a broader indication does not automatically translate into rapid procedure growth. Provider education, payer policies, patient identification, scheduling capacity and treatment adherence determine how much of a regulatory expansion becomes revenue.

Reimbursement is a genuine competitive asset

Neuronetics estimates that more than 104 major private insurers, including the 25 largest private insurers and federal healthcare programs, maintain TMS coverage policies representing more than 300 million covered lives, or roughly 95% of U.S. payer-covered lives. That is important because interventional mental-health adoption is constrained not only by clinical acceptance but also by who can authorize, supervise and bill for treatment.

In April 2026, Optum/UnitedHealthcare/United Behavioral Health expanded its clinical policy to permit psychiatric mental-health nurse practitioners to order, supervise and administer NeuroStar in jurisdictions with full practice authority. Neuronetics said the change applied across 26 states and Washington, D.C., reaching approximately 34.8 million covered lives. The practical opportunity is broader provider capacity, especially where psychiatrist availability is limited. The practical risk is that coverage policy does not guarantee utilization: clinics must still recruit eligible patients and run efficient schedules.

Clinical-data claims require context

Neuronetics promotes a very large real-world outcomes dataset. The scale can support physician confidence, payer discussions and product development. Nevertheless, investors should distinguish registry evidence from randomized controlled evidence. The company’s own footnotes note that registry patients were treated under real-world conditions and could have received concomitant medications or other depression treatments. These data are commercially useful, but they do not eliminate confounding variables.

Safety and treatment friction

The most common disclosed side effect is transient pain or discomfort at or near the treatment site. The company reports a rare seizure risk of less than 0.1% per patient, and NeuroStar should not be used in patients with non-removable conductive metal in or near the head. Beyond formal safety, the business must manage treatment friction: TMS generally requires repeated appointments, and patient access, transportation, scheduling and authorization can affect completion rates and clinic utilization.

Competition

Neuronetics identifies direct TMS competitors including BrainsWay, Apollo TMS, Magstim, MagVenture, CloudTMS and Nexstim. It also competes with antidepressants, esketamine, electroconvulsive therapy and emerging treatment modalities. The competitive question is not simply which device works. It includes treatment time, workflow, reimbursement support, provider economics, evidence quality, brand recognition and the ability to identify and convert patients.

Technology development and neuronavigation

In May 2026, Neuronetics announced a preferred partnership with ANT Neuro to offer the visor2 neuronavigation system alongside NeuroStar. The technology adds real-time spatial tracking and 3D visualization intended to improve targeting visibility and consistency. A broader rollout is planned for the second half of 2026. Commercial terms were not disclosed, so investors should treat the collaboration as a product-enhancement catalyst rather than assume a specific revenue contribution.

At year-end 2025, Neuronetics reported 62 issued or allowed patents and 17 pending patent applications worldwide. The portfolio includes TMS technology, system design, methods, manufacturing processes and potential future products. Some patents begin expiring in 2026, but the portfolio extends into later years. As with most device businesses, commercial durability depends on more than patents: installed-base relationships, evidence, service, reimbursement and sales execution matter heavily.

Greenbrook: The Acquisition That Changed the Company

Neuronetics completed the Greenbrook acquisition effective December 9, 2024. Greenbrook became a wholly owned subsidiary, and its results have been included in Neuronetics’ consolidated financial statements since the closing date. The transaction transformed STIM’s reported scale and financial profile.

Before closing, Madryn converted Greenbrook debt and interim funding into Greenbrook equity. Madryn held 95.3% of Greenbrook immediately before the transaction-related exchange and emerged as Neuronetics’ largest shareholder. Neuronetics issued approximately 25.3 million common shares and paid $4.2 million in cash consideration. This history matters because the acquisition, ownership concentration, board representation and capital structure are connected.

The reported 99% revenue growth in 2025 was driven mainly by including Greenbrook for a full year. The more informative comparison is adjusted pro forma: Neuronetics reported 15% full-year pro-forma growth, while Greenbrook clinic revenue increased 28% on an adjusted pro-forma basis. Those numbers indicate that the combination was not merely an accounting illusion. The underlying platform grew, especially in clinics.

At the same time, gross margin fell to 48.5% in 2025 from 72.3% in 2024 because clinic services became a major part of the mix. This is not automatically negative: a lower-margin business can create more gross-profit dollars and strategic control. But valuation must reflect the blended model. STIM should not be valued as a pure high-margin medical-device company unless the recurring device/session contribution reaccelerates and clinic economics become sustainably profitable.

The May 2026 presentation listed 93 Greenbrook clinics nationwide and 84 REMS-certified treatment centers offering SPRAVATO. It also described more than 800 NeuroStar customer sites. Management’s growth plan includes referral automation, digital and direct-to-consumer targeting, standardized operations, centralized support and a broader continuum of care. These initiatives are plausible; the evidence investors need is improved appointment volumes, revenue per clinic, contribution margin and cash conversion.

Q1 2026 Financial Deep Dive

Q1 showed progress, but not yet financial self-sufficiency. Revenue increased, clinic growth remained healthy, operating expenses declined and cash burn improved substantially from the prior year. However, treatment-session revenue fell, gross margin compressed and unrestricted cash declined sharply after operating use and debt repayment.

Revenue quality

Clinic revenue did the heavy lifting. The company attributed growth to expansion following the Greenbrook acquisition and continued SPRAVATO growth, including buy-and-bill activity. System placements were positive, but treatment-session revenue declined because of lower volumes. That divergence matters. A system shipment adds potential future capacity; recurring session revenue shows whether installed capacity is being used.

Margin quality

Gross profit increased by about $0.4 million, while revenue increased by about $2.5 million. Gross margin fell 230 basis points. Management attributed the decline primarily to clinic revenue mix. Investors should watch whether clinic scale improves labor and facility absorption or whether the mix keeps consolidated margin near the lower end of guidance.

Expense discipline

Sales and marketing expense fell 11% to $10.7 million, helped by lower personnel costs, reduced marketing-program spending and a favorable bad-debt adjustment. General and administrative expense was nearly flat at $13.0 million. Research and development declined 16% to $1.4 million. Lower expenses supported the operating-loss improvement, but sustained growth cannot rely only on cuts. The company needs enough investment to maintain the commercial funnel and product competitiveness.

Interest consumes operating progress

Interest expense of $2.3 million represented roughly one quarter of the Q1 operating loss. The debt facility’s floating rate is 7.0% plus the greater of 4.5% or one-month SOFR, establishing a minimum rate of 11.5%. The company reduced principal by $5 million in March, but the remaining $65 million balance is still expensive. A business can improve at the operating line while common-equity value remains constrained by financing costs.

2026 Guidance and the Run-Rate Math

Management reaffirmed the following full-year outlook with Q1 results:

What the revenue guide requires

After Q1 revenue of $34.454 million, Neuronetics needs another $125.546 million to reach the low end and $131.546 million to reach the high end. That equals an average of approximately $41.85 million–$43.85 million per quarter across Q2, Q3 and Q4. The company already demonstrated a $41.8 million quarter in Q4 2025, so the target is operationally possible, but it requires a clear seasonal and execution step-up from Q1.

What “mid-single-digit” Q2 growth may imply

Q2 2025 revenue was $38.108 million. A purely illustrative 4%–6% growth range would produce approximately $39.6 million–$40.4 million for Q2 2026. Management did not define an exact percentage, so this is not company guidance. It is a monitoring range that helps investors test whether the reported result is broadly consistent with the language.

The cash-flow bridge is much harder

Neuronetics used $9.421 million of operating cash in Q1. To finish 2026 inside the negative $13 million to negative $17 million range, it can use only about $3.6 million–$7.6 million of additional operating cash over the final three quarters. That math requires a substantial improvement in working capital and operating losses. It may also depend on seasonality and collections. The Q2 cash number is therefore more important than a small revenue beat or miss.

Gross-margin path

Q1 gross margin of 46.9% was just below the full-year 47%–49% range. A modest improvement would return the company to guidance, but the composition matters. Clinic growth can support total gross-profit dollars while keeping percentage margin under pressure. Treatment-session stabilization, system mix, clinic productivity and reimbursement collections will determine whether the company can move toward the upper half of the range.

Cash, Debt and the Going-Concern Warning

This is the most important section of the Stock Hub. At March 31, 2026, Neuronetics held $13.214 million of unrestricted cash and cash equivalents plus $5.750 million of restricted cash. Total cash including restricted cash was $18.964 million, down from $34.134 million at year-end. The decline reflected operating cash use, a $5 million debt payment and other financing flows.

The Perceptive facility

Neuronetics had $65 million outstanding under its Perceptive credit facility, which matures in July 2029. There are no scheduled principal repayments before maturity. The facility is secured by a first-priority security interest in substantially all company assets, including intellectual property, and includes quarterly trailing-revenue and minimum-liquidity covenants.

The interest rate resets monthly and equals 7.0% plus the greater of 4.5% or one-month term SOFR. This means the rate cannot fall below 11.5%. The facility therefore imposes a meaningful cash-interest burden even if operating performance improves.

The March 31, 2027 covenant

Neuronetics stated in its Q1 10-Q that it currently projects trailing-twelve-month revenue for the period ending March 31, 2027 below the minimum required by the credit agreement. If the company fails the covenant, the lender may call the facility at its discretion. Neuronetics also stated that it is not projected to have enough liquidity to repay the loan if called.

This disclosure led the company to state that substantial doubt exists about its ability to continue as a going concern. That phrase should not be sensationalized: it does not mean failure is certain. Companies can amend covenants, refinance debt, raise equity, improve performance or pursue strategic transactions. But it does mean that the current plan does not fully eliminate a material financing risk.

What would reduce the risk

• better-than-planned revenue and clinic productivity;
• clear evidence that operating cash use is approaching breakeven;
• a covenant amendment well before March 2027;
• a refinancing with manageable interest and dilution;
• asset monetization or a broader strategic transaction;
• raising capital at a materially higher share price rather than under distress.

What would increase the risk is the mirror image: weak session volumes, stalled clinic growth, low gross margin, continued heavy cash use, low-price ATM issuance, lender concessions with additional warrants or a strategic process that fails to produce attractive terms.

Capital Structure and Dilution Risk

At May 1, 2026, Neuronetics reported 69,587,840 common shares outstanding. That basic count does not capture all potential equity dilution. At March 31, the company also had approximately 1.95 million warrants, 1.091 million stock options, 5.516 million unvested RSUs and 0.995 million unvested performance RSUs excluded from diluted EPS because the company reported a loss.

A simple addition produces a potential share base of approximately 79.1 million before applying the treasury-stock method, vesting conditions, exercise prices, forfeitures and future grants. This is not a forecast of immediate dilution, but it is a more conservative lens than basic shares alone.

The ATM overhang

Neuronetics established a $50 million at-the-market program in July 2025. During 2025, it sold approximately 2.262 million shares at an average price of $3.68, generating $8.3 million of gross proceeds and $7.8 million net. At March 31, 2026, approximately $41.7 million remained available.

The ATM is simultaneously a survival tool and an equity risk. It gives management flexibility to fund operations or strengthen liquidity without launching a fully marketed deal. However, at a low share price, raising a meaningful amount requires issuing a large number of shares. For perspective, $20 million of gross issuance at $1.62 would equal roughly 12.3 million shares before fees—about 18% of the May 1 basic share count. This is illustrative arithmetic, not a prediction of issuance.

Warrants and lender economics

The outstanding warrants include 1.125 million expiring in July 2034, 600,000 expiring in December 2034 and 225,000 expiring in August 2035, all with a $0.94 exercise price. Warrant exercise could provide cash, but it also increases the share count. Future covenant amendments could add further equity-linked consideration; investors should examine every debt amendment rather than focus only on stated principal and interest.

Management, Ownership and Activist Pressure

Leadership reset

Dan Reuvers became president and CEO on March 23, 2026. He brought more than three decades of medical-device experience and a mandate centered on growth, earnings and cash flow. The timing is important: he inherited a newly integrated clinic platform, a high-cost debt structure and a covenant issue disclosed weeks later.

Former CFO Steven Pfanstiel departed effective May 1 for an external opportunity, with the company stating that the decision did not result from a disagreement. Francis X. Brown III became interim principal financial and accounting officer. In June, Neuronetics appointed Robert Greene as senior vice president of sales. These changes can refresh execution, but they also create transition risk during a financially sensitive period.

Concentrated ownership

The 2026 proxy reported Madryn and related entities at 20.737 million shares, or 29.8%; Jorey Chernett at 9.779 million shares, or 14.1%; and Parian Ultreia at 4.885 million shares, or 7.0%. Madryn also has board representation and rights connected to its ownership. Concentrated ownership can align sophisticated capital with long-term outcomes, but it can also reduce the influence of smaller holders and create overhang if a large investor seeks liquidity.

The 2025 10-K stated that Madryn had requested registration rights that would facilitate its ability to sell shares. Registration does not mean a sale must occur, but the possibility matters for supply and governance.

Pointillist’s strategic-alternatives campaign

In April 2026, Chernett called for an immediate comprehensive review of strategic alternatives, including a potential sale of Neuronetics’ TMS business. The filing argued that the existing structure was not maximizing value and that separating or divesting the TMS business could improve financial flexibility. Neuronetics responded that it agreed the market valuation did not fully reflect the business and remained open to constructive engagement.

No formal strategic-review process or signed transaction had been announced as of July 20. Investors should therefore classify a sale, separation or take-private as optionality—not a confirmed catalyst. Activist pressure can accelerate value recognition, but it can also distract management, complicate lender discussions or lead to a transaction that favors one stakeholder group over another.

Insider accumulation

SEC Form 4 filings showed additional purchases by Chernett in April and May 2026. The May 19 filing reported another 100,000-share purchase. Continued buying can signal conviction, but it does not resolve the company’s liquidity needs or guarantee that the activist’s preferred strategic outcome will occur.

Annual-meeting signal

All directors were elected at the May 2026 annual meeting, but several nominees received substantial withheld votes. The 2026 equity incentive plan passed with approximately 23.8 million votes for, 16.7 million against and 0.8 million abstaining. This does not change corporate control, but it indicates meaningful shareholder disagreement around governance and compensation.

Timeline: How the Current Setup Developed

Catalyst Calendar

Bull, Base and Bear Scenarios

These are analytical scenarios, not forecasts or recommendations. They organize the variables that can drive enterprise value and common-equity outcomes.

Valuation: Why Basic Market Cap Is Not Enough

At the July 17 close of $1.62 and approximately 69.588 million basic shares, Neuronetics’ equity value was about $112.7 million. Adding $65 million of gross debt and subtracting $13.214 million of unrestricted cash produces an illustrative enterprise value of roughly $164.5 million. Against the $163 million midpoint of 2026 revenue guidance, that is approximately 1.01 times enterprise value to revenue.

If the calculation uses the gross potential share base of roughly 79.14 million at the same price, equity value rises to approximately $128.2 million and enterprise value to about $180.0 million, or roughly 1.10 times the revenue midpoint. These calculations exclude lease liabilities and future cash burn, and they do not assume that all awards become outstanding immediately.

Illustrative EV/revenue sensitivity

The following table converts hypothetical enterprise-value multiples into equity value after subtracting net debt of approximately $51.8 million, then divides by the gross potential share base of approximately 79.14 million. It is educational scenario math, not a price target.

Assumptions: FY2026 revenue midpoint of $163M; gross debt of $65M; unrestricted cash of $13.214M; gross potential share base of approximately 79.14M. The table ignores future cash burn, restricted cash, lease liabilities, transaction costs, ATM issuance, warrant exercise proceeds, treasury-stock accounting and changes in debt terms.

Why a revenue multiple has limits

Revenue multiples are convenient because Neuronetics is not profitable, but they do not measure cash generation or capital intensity. The device, recurring-session and clinic streams have different margins and risk. A 1.0x multiple may be expensive if the company must repeatedly issue shares to service debt and fund clinics. A higher multiple may be justified if the platform reaches positive cash flow, resolves the covenant and demonstrates durable growth.

The correct valuation hinge is therefore not a single multiple. It is the value of the operating platform after the financing path is incorporated. Investors should update the enterprise-value bridge after every earnings report, debt amendment and equity issuance.

Technical and Trading Map

This section is descriptive, not predictive. STIM closed July 17 at $1.62 after trading as high as $2.33 on July 16 on unusually heavy volume. The rapid reversal confirms that the stock is capable of large moves without a smooth fundamental repricing process.

Because the warrant exercise price is $0.94 and the company has an active ATM, strength can attract additional supply. Conversely, concentrated ownership, activist involvement and a relatively small public equity value can amplify positive event reactions. Volume and filing activity should be watched together.

Q2 Earnings Checklist: The Numbers That Matter

Red Flags That Should Not Be Minimized

Bottom Line

Neuronetics has assembled one of the more interesting small-cap platforms in interventional mental health. NeuroStar provides a recognized TMS franchise, recurring treatment-session economics and a large installed footprint. Greenbrook adds direct access to patients, clinic revenue, SPRAVATO delivery and a potential infrastructure layer for future therapies. Q1 2026 showed real operating improvement: revenue grew, clinic revenue remained strong, expenses fell and cash use improved sharply year over year.

But the company’s own filing makes the priority unmistakable. Current projections place the March 31, 2027 trailing-revenue covenant below the required threshold, and the company does not expect to have enough liquidity to repay the facility if the lender calls it. That risk means STIM is not merely a “cheap revenue” story. It is a financed-growth story in which the value of the operating platform must be measured after debt, interest, restricted liquidity, leases, warrants, RSUs and possible ATM issuance.

The Q2 report should be judged through this lens. A revenue beat is useful. A clinic-growth beat is better. The most important evidence is a sharp improvement in cash conversion, a credible covenant solution and proof that the combined platform can approach self-funding before external capital becomes punitive.

Evidence confidence: high for reported financials, debt terms, ownership and official company developments; moderate for the expected Q2 reporting window because the exact date had not been announced. Underwriting status: active watchlist / financing-constrained. Key unresolved items: Q2 cash use, ATM activity after March 31, permanent CFO appointment, covenant negotiations and any formal strategic-alternatives process.

Primary Sources and Verification Links

1. Neuronetics Form 10-Q for the quarter ended March 31, 2026 — financial statements, liquidity, debt, covenants, ATM, warrants and going-concern disclosure.
2. Neuronetics Q1 2026 financial and operating results — revenue, guidance, operating metrics and Optum policy update.
3. Neuronetics 2025 Form 10-K — business model, Greenbrook acquisition, competition, reimbursement, patents and risk factors.
4. Neuronetics Q4 and FY2025 results — reported and pro-forma growth, clinic revenue, margin and cash flow.
5. May 2026 corporate presentation filed with the SEC — footprint, strategic initiatives, patient/treatment scale and guidance.
6. Neuronetics–ANT Neuro collaboration — visor2 neuronavigation integration.
7. Optum/UHC/UBH policy expansion — psychiatric nurse-practitioner access.
8. CTMSS 2026 research update — real-world TMS research themes.
9. Dan Reuvers appointment — CEO transition.
10. CFO transition announcement.
11. May 2026 Form 8-K — interim principal financial and accounting officer arrangements.
12. Pointillist/Chernett Schedule 13D amendment — strategic-alternatives request and potential TMS-business sale.
13. Neuronetics response to Pointillist.
14. 2026 proxy statement — beneficial ownership, board and governance data.
15. 2026 annual-meeting results — director votes and equity-plan approval.
16. May 2026 Chernett Form 4 — insider purchase disclosure.
17. July 2026 B. Riley event announcement.
18. Neuronetics Investor Relations — official news, presentations and event calendar.
19. Historical market-price reference — July 17 close, volume and market capitalization. Third-party market data; verify with a live brokerage feed.